U.K. Midcaps Have a New Biggest Loser as Analysts Cut Indivior
- Plunge makes drug-maker worst performer on FTSE 250 in 2018
- Court ruling to see earnings hit by copycat drugs: analysts
Photographer: George Frey/Bloomberg
This article is for subscribers only.
Indivior Plc extended its two-day plunge to more than 50 percent after a court ruling that clears the way for a rival to resume selling a copycat version of one of its blockbuster opioid addiction treatments.
The share-price dive makes the company spun-out of consumer staples giant Reckitt Benckiser Group Plc four years ago the worst-performing stock on the U.K. midcap FTSE 250 index in 2018, down about 77 percent.